Automation-ready blowdown evaporator available from Porvair Sciences
The Ultravap Levante will appeal to the budget-conscious laboratory who may wish to automate their sample dry-down bottleneck in the future.
The Ultravap Levante from Porvair Sciences is a next generation nitrogen blowdown evaporator designed to meet the needs of the modern automated laboratory.
The Ultravap Levante comes with an RS232 connection and a remote command set enabling it to connect to and be operated from most commercially available robotic liquid handling systems. Porvair have positioned this automation-ready microplate evaporator to appeal to the budget-conscious laboratory who may wish to automate their sample dry-down bottleneck in the future.
With the Ultravap Levante users get full-colour touchscreen graphic displays, an integrated auto-ranging power supply and built-in solvent fume venting. Combined with real-time run displays showing actual gas temperature, gas flow rate and stage height the Ultravap Levante puts users in full control of their evaporation protocols. Offering multi-step ramped programming with full alphanumeric program naming, the Levante offers the capability to automatically handle even complex evaporation protocols effortlessly.
Designed around a standard ANSI/SLAS plate 'nest' to accept most microplate formats and tube racks, the Ultravap Levante can accommodate tubes up to 80mm in height in a variety of configurations to allow the use of 2 Dram vials, 1.5 mL HPLC vials, bar-coded tubes in racks and many other common formats. Evaporator heads are made to match these formats in 24-, 48-, 96- and 384-well configurations. The unique Porvair 96-well spiral needle head, which creates a vortex in certain plates to speed up evaporation, can also be used on the Ultravap Levante.
The Ultravap Levante can be operated from an in-house supply of nitrogen/clean dry air or from a gas cylinder. The blowdown technique employed by the Ultravap Levante has been widely adopted by labs worldwide for removing chromatography solvents such as dichloromethane, acetonitrile, methanol and hexane.
Related News
-
News Patients vs Pharma – who will the Inflation Reduction Act affect the most?
The Inflation Reduction Act brought in by the Biden administration in 2022 aims to give better and more equitable access to healthcare in the USA. However, pharma companies are now concerned about the other potential costs of such legislation. -
News CPHI Podcast Series: What does the changing US Pharma market mean for industry and patients alike?
In this week's episode of the CPHI Podcast Series Lucy Chard, Digital Editor for CPHI Online is joined by James Manser to discuss the political and market changes in the US pharma field. -
News CPHI Barcelona Annual Report illuminates industry trends for 2024
The CPHI Annual Survey comes into it’s 7th year to report on the predicted trends for 2024. Over 250 pharma executives were asked 35 questions, with their answers informing the industry landscape for the next year, spanning all major pharma marke... -
News Which 10 drugs are open to price negotiation with Medicare in the USA?
The Centres for Medicare & Medicaid Services, under the Biden administration in the USA, has released a list of the 10 drugs that will be open to price negotiations as part of the new legislation under the Inflation Reduction Act (IRA). -
News EU Medical Devices Regulation causes unintended disappearances of medical devices for children, doctors state
Doctor groups and associations have appealed to the EU to correct the EU Medical Devices Regulation law that may cause unintended shortages of essential drug and medical devices for children and rare disease patients. -
News 10 Major Drug Approvals So Far in 2023
Last year, 37 novel drugs were approved by the FDA, this was a high number for such a category, and covered many fields including oncology, demonstrating how promising further research is, and how it is only continuing to build. To date, there are alre... -
News Detecting Alzheimer's disease with a simple lateral flow test
A novel rapid diagnostic test for early-stage Alzheimer's disease has been developed using a biomarker binder from Aptamer Group along with technology from Neuro-Bio, the neurodegenerative disease experts. -
News CPHI Podcast Series: outsourcing and manufacturing trends
Listen to the CPHI Podcast Series this June to hear Gil Roth of the PBOA speak with Digital Editor Lucy Chard about the biggest trends and topics to watch in pharma outsourcing and manufacturing at the minute.
Position your company at the heart of the global Pharma industry with a CPHI Online membership
-
Your products and solutions visible to thousands of visitors within the largest Pharma marketplace
-
Generate high-quality, engaged leads for your business, all year round
-
Promote your business as the industry’s thought-leader by hosting your reports, brochures and videos within your profile
-
Your company’s profile boosted at all participating CPHI events
-
An easy-to-use platform with a detailed dashboard showing your leads and performance